Insulin mediated improvement in glycemic control in elderly with type 2 diabetes mellitus can improve depressive symptoms and does not seem to impair health-related quality of life

Diabetology & Metabolic Syndrome

L. Zajdenverg¹  M. Rodacki¹  V. A. Queiroz¹  M. Tostes¹  R. A. Oliveira¹ 

[1] Nutrology and Diabetes Section, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

关键词: Insulin;    Elderly;    Diabetes mellitus;    Depression;    Health- related quality of life;   

Others  :  1219828
DOI  :  10.1186/s13098-015-0052-1

 received in 2014-11-09, accepted in 2015-06-16,  发布年份 2015

【 摘 要 】

Background and objectives

Type 2 diabetes (T2D) is very prevalent among the elderly. Insulin therapy is often required for glycemic control. The association of starting this therapy with depressive symptoms as well the health-related quality of life (HRQoL) is unknown among the elderly patients.

Aims

Evaluate the association of starting insulin therapy depressive symptoms as well with HRQoL of elderly people with T2D.

Methods

36 T2D participants (67.9 % females, age 66.5 years ± 5.1) were recruited, 26 of whom completed the follow-up. Generic (Short-Form 36 Health Survey - SF-36) and specific (Problem Areas in Diabetes - PAID) HRQoL questionnaires, Beck Depression Inventory (BDI), clinical, laboratorial and socio-demographic data were recorded on baseline and 6 months after the beginning of insulin treatment.

Results

There was a reduction in the BDI score after the use of insulin, which means an improvement in depressive symptoms (Before/After: median – 10.5 / 7; p = 0008). There were no statistically significant differences in HRQoL scores between the two time periods There was also a reduction in HbA1c (Before/After: median – 8.7/7.9). Otherwise, there were no statistically significant differences in: BMI (28.1/28.3); Abdominal circumference:(100.5/99.5) and chronic complications status.

Conclusion

Insulin therapy in elderly people with type 2 diabetes can lead to an improvement of depressive symptoms and does not seem to affect negatively HRQoL of the participants.

【 授权许可】

   
2015 Oliveira et al.

【 参考文献 】

• [1]International Federation of Diabetes (IDF).. www.idf.org/diabetesatlas/Se/the-global-burden/2013 webcite
• [2]Kirkman S, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al.: Diabetes in older adults: a consensus report. J Am Geriatr Soc 2012, 60(12):2342-56.
• [3]Funnel MM: Quality of life and insulin therapy in type 2 diabetes mellitus. Insulin 2008, 3(1):31-6.
• [4]Shah S, Zilov A, Malek R, Soewondo P, Bech O, Litwak L: Improvement in quality of life associated with insulin analogue therapies in people with type 2 diabetes mellitus: Results from the A1chieve observational study. Diabetes Res Clin Pract. 2011, 94:364-70.
• [5]Plank J, Siebenhofer A, Berghold A, et al.: Systematic and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med. 2005, 165:1337-44.
• [6]Ashwell SG, Bradley C, Stephens JW, Witthause E, Home PD: Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care. 2008, 31:1112-7.
• [7]Horvath K, Jeider K, Berghold A, et al.: Long-acting insulin analogues versus NPH insulin for type 2 diabetes. Cochrane Database Syst Rev. 2007., 2Article ID CD005613
• [8]Tabak AG, Akbaraly TN, Batty GD, Kivimaki M: Depression and type 2 diabetes: a causal association? Lancet Diabetes Endocrinol 2013, 2(3):236-45.
• [9]Li C, Barker L, Ford ES, Zhang X, StrineTW MAH: Diabetes and anxiety in US adults: findings from the 2006 behavioral risk factor surveillance system. Diabet Med. 2008, 25:878-81.
• [10]Chmiel-Perzynska I, Perzynski A, Derkacz M: The influence of initiating insulin therapy on revealing psychic disturbances in patients suffering from type 2 diabetes. Diabetol Doswiadczalna I Kliniczna. 2010, 10:41-5.
• [11]Aguiar CCT, Vieira APGF, Carvalho AF, Montenegro-Junior RM: Assessment instruments for a Health-Related Quality of Life in diabetes mellitus. Arq Bras Endocrinol Metabol 2008, 52(6):931-9.
• [12]Gross C, Scain SS, Scheffel R, Gross JL, Hutz CS: Brazilian version of the Problem Areas in Diabetes Scale (B-PAID): Validation and identification of individuals at high risk for emotional distress. Diabetes Res Clin Pract 2007, 76(3):455-9.
• [13]Welch GW, Jacobson AM, Polonsky WH: The problem areas in diabetes scale. Diabetes Care. 1997, 20:760-6.
• [14]Polonsky WH, Jacobson AM, Anderson BJ: Assessment of diabetes-related distress. Diabetes Care. 1995, 18:754-60.
• [15]Gorestein C, Andrade L: Validation of a Portuguese version of the Beck Depression Inventory and the State-Trait Anxiety Inventory in Brazilian subjects. Braz J Med Biol Res 1996, 29(4):453-7.
• [16]Nicolau J, Rivera R, Frances C, Chacartegui B, Masmiquel L: Treatment of depression in type 2 diabetic patients: effects on depressive symptoms, quality of life and metabolic control. Diabetes Res Clin Pract 2013, 101(2):148-52.
• [17]Daniele TM, Bruin VM, Oliveira DS, Pompeu CM, Forti AC: Associations among physical activity, comorbidities, depressive symptoms and health-related quality of life in type 2 diabetes. Arq Bras Endocrinol Metabol 2013, 57(1):44-50.
• [18]Hosoya T, Matsushima M, Nukaryia K, Utsunomiya K: The relationship between the severity of depressive symptoms and diabetes-related emotional distress in patients with type 2 diabetes. Intern Med. 2012, 51:263-9.
• [19]Eljedi A, Mikolajczyk RT, Kraemer RS, Laaser U: Health-related quality of life in diabetic patients and controls without diabetes in refugees camps in Gaza strip: a cross-sectional study. BMC Public Health. 2006, 6:268-70. BioMed Central Full Text
• [20]Zhang Q, Zhang N, Hu H, He Y, Chen MW, Wang XY, et al.: Effect of intensive blood glucose control on quality of life in elderly patients with type 2 diabetes in Anhui Province. Chin Med J 2011, 124(11):1616-22.
• [21]Wandel PE: Quality of life of patients with diabetes mellitus. An overview of research in primary health care in the nordic countries. Scand J Prim Health Care 2005, 23(2):68-74.
• [22]Akinci F, Yildirim A, Gözü H, Sargin H, Orbay E, Sargin M: Assessment oh health-related quality of life (HRQoL) of patients with type 2 diabetes in Turkey. Diabetes Res Clin Pract 2008, 79(1):117-23.
• [23]Fal AM, Jankowska B, Uchmanowicz SM, Panaszek B, Polanski J: Type 2 quality of life patients treated with insulin and oral hypoglicemic medication. Acta Diabetol. 2011, 48:237-42.
• [24]Kelley K, Aricak OT, Light RP, Agarwal R: Protenuria is a determinant of quality of life in diabetic nephropathy: modeling lagged effects with path analysis. Am J Nephrol 2007, 27(5):488-94.
• [25]Pontiroli AE, Miele L, Morabito A: Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab. 2011, 13:1008-19.
• [26]Kamoi K, Miyakoshi M, Maruyama R: A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by ITR-QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. Diabetes Res Clin Pract. 2004, 64:19-25.